GlassScriptPhysician profile
Casey Forman
NPI 1750055307
$5,661.05
in general payments reported to CMS, 2019-2025
26 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,335 · 2023: $1,742 · 2024: $1,323 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.64 |
| Education | $102.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,829.78 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $651.85 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $534.08 | 2022-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $486.24 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $301.19 | 2022-2025 | Stelara, Tremfya |
| Genzyme Corporation | $298.82 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $177.95 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $167.54 | 2024-2025 | Zymfentra, Vegzelma |
| Qol Medical, LLC | $139.31 | 2022-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $134.59 | 2024 | Endoflip, Pillcam |
| Merck Sharp & Dohme LLC | $109.54 | 2023-2024 | Dificid, Zinplava |
| Enterra Medical, INC. | $109.17 | 2023-2025 | |
| Celgene Corporation | $106.54 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $93.46 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $83.20 | 2023-2024 | Linzess |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $67.73 | 2023 | |
| Amgen INC. | $64.79 | 2022-2023 | Amjevita |
| Madrigal Pharmaceuticals | $55.61 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $51.00 | 2023 | Ocaliva |
| Pfizer INC. | $49.44 | 2025 | |
| Novo Nordisk INC | $42.19 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $26.32 | 2023 | Monoferric |
| Ferring Pharmaceuticals INC. | $25.06 | 2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $22.55 | 2025 | Iqirvo |
| Organon LLC | $17.60 | 2025 | Hadlima, Renflexis |
| W. L. Gore & Associates, INC. | $15.50 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.